<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776539</url>
  </required_header>
  <id_info>
    <org_study_id>EL-008</org_study_id>
    <nct_id>NCT03776539</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eloxx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eloxx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 - Pharmacokinetics in Patients with Impaired Renal Function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a two-center, Phase 1, open-label, single-dose, one-period, four-parallel-group,&#xD;
      PK study in subjects with various severities of renal dysfunction and healthy volunteers.&#xD;
&#xD;
      Subjects will be categorized in 4 groups:&#xD;
&#xD;
      Group 1: subjects with mild renal impairment Group 2: subjects with moderate renal impairment&#xD;
      Group 3: subjects with severe renal impairment Group 4 (control group): subjects with normal&#xD;
      renal function&#xD;
&#xD;
      The mild (group 1) and moderate (group 2) patients with renal disease will be dosed first, in&#xD;
      a parallel fashion. At this point, interim PK analyses will be performed and a safety&#xD;
      committee composed of Sponsor and Contract Research Organization (CRO) members will jointly&#xD;
      review the PK data before dosing the patients with severe renal disease (group 3). Control&#xD;
      subjects (group 4) will be recruited after the recruitment of groups 1 to 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects will be categorized in 4 groups:&#xD;
Group 1: subjects with mild renal impairment&#xD;
Group 2: subjects with moderate renal impairment&#xD;
Group 3: subjects with severe renal impairment&#xD;
Group 4 (control group): subjects with normal renal function</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters- Plasma AUC0-24</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, and 24 hours after dosing</time_frame>
    <description>Area under the curve (AUC0-24) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters- Plasma Cmax</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 36, 48, 72, and 168 (Day 8) hours after dosing</time_frame>
    <description>Peak Plasma Concentration (Cmax) of ELX-02 following a single subcutaneous (SC) dose in subjects with normal renal function, mild, moderate, or severe renal impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 36, 48, 72, and 168 (Day 8) hours after dosing</time_frame>
    <description>Area under the curve (AUC0-inf) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters - Plasma Tmax</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, and 24 hours after dosing.</time_frame>
    <description>Time to maximum concentration (Tmax) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - Ae0-t</measure>
    <time_frame>Pre-dose (first void in the morning of Day 1), 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36, 36-48, and 48-72 hours post-dose</time_frame>
    <description>Cumulative amount of unchanged drug excreted into urine (Ae0-t) of ELX-02 following a single subcutaneous (SC) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetic Parameter - Rmax</measure>
    <time_frame>Pre-dose (first void in the morning of Day 1), 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36, 36-48, and 48-72 hours post-dose</time_frame>
    <description>Maximum rate of urinary extraction (Rmax) of ELX-02 following a single subcutaneous (SC) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Treatment-Emergent Adverse Events (TEAEs) [Safety]</measure>
    <time_frame>1-8 days</time_frame>
    <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>ELX-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: ELX-02</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX-02</intervention_name>
    <description>ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.</description>
    <arm_group_label>ELX-02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, non-smoker and/or light smoker&#xD;
&#xD;
          2. Have a diagnosis of renal impairment that has been stable, without any significant&#xD;
             change in overall disease status in the last 3 months prior to screening.&#xD;
&#xD;
          3. Have an estimated glomerular filtration rate (eGFR) expressed in mL/min/1.73 m2&#xD;
             (Modification of Diet in Renal Disease 4-variable [MDRD4] equation) at screening&#xD;
             within the range of:&#xD;
&#xD;
               1. Group 1 - Mild Group: 60 - 89 mL/min/1.73 m2;&#xD;
&#xD;
               2. Group 2 - Moderate Group: 30 - 59 mL/min/1.73 m2;&#xD;
&#xD;
               3. Group 3 - Severe Group: &lt; 30 mL/min/1.73 m2 not requiring dialysis. eGFR results&#xD;
                  that are deemed inconsistent with the usual stage of renal impairment may be&#xD;
                  repeated. Subjects are categorized into severity group at screening. If the eGFR&#xD;
                  scores change on Day-1 or other visit due to a non-clinically significant change&#xD;
                  in clinical status or laboratory result, the subject keeps the original severity&#xD;
                  group.&#xD;
&#xD;
          4. Subject may have stable treated medical illnesses and underlying diseases producing&#xD;
             the renal impairment such as diabetes, hypertension, or cardiovascular disease,&#xD;
             providing that, in the opinion of the PI, the disease is stable.&#xD;
&#xD;
          5. Have normal or non-clinically significant findings at physical examination, vital&#xD;
             signs and electrocardiogram (ECG) and normal limits or non-clinically significant&#xD;
             deviations in clinical laboratory evaluations at screening.&#xD;
&#xD;
          6. Other than renal impairment, have no other conditions which may significantly impact&#xD;
             study drug absorption or metabolism.&#xD;
&#xD;
          7. Stable medical regimen, deemed not to interact with study drug PK, for 14 days prior&#xD;
             to dosing, except for routine daily management of electrolytes (e.g. potassium),&#xD;
             acid-base, or other associated disorders expected in patients with renal impairment.&#xD;
&#xD;
          8. Females of childbearing potential who are sexually active with a non-sterile male&#xD;
             partner (sterile male partners are defined as men vasectomized since at least 6&#xD;
             months) must be willing to use acceptable contraceptive method throughout the study&#xD;
             and for 30 days after study drug administration.&#xD;
&#xD;
          9. Male subjects who are not vasectomized for at least 6 months, and who are sexually&#xD;
             active with a non-sterile female partner (sterile female partners include&#xD;
             post-menopausal females and surgically sterile females) must be willing to use&#xD;
             acceptable contraceptive method from dosing until at least 90 days after study drug&#xD;
             administration.&#xD;
&#xD;
         10. Male subjects (including men who have had vasectomy) with a pregnant partner must&#xD;
             agree to use a condom from dosing until at least 90 days after study drug&#xD;
             administration.&#xD;
&#xD;
         11. Male subjects must be willing not to donate sperm until 90 days following study drug&#xD;
             administration.&#xD;
&#xD;
         12. Able to understand and willing to sign the Informed Consent Form (ICF) and comply with&#xD;
             the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable renal function or acute exacerbation of renal disease within 14 days of study&#xD;
             drug administration, as indicated by recent history or worsening of clinical and/or&#xD;
             laboratory signs of renal impairment.&#xD;
&#xD;
          2. Has a functioning renal transplant.&#xD;
&#xD;
          3. Major illness or surgery within 4 weeks prior to dosing.&#xD;
&#xD;
          4. Clinically significant unstable medical condition or history of any illness that may&#xD;
             increase the risk associated with study participation or investigational drug&#xD;
             administration or may interfere with the interpretation of study results and would&#xD;
             make the subject inappropriate for entry into this study.&#xD;
&#xD;
          5. Positive test for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at&#xD;
             screening.&#xD;
&#xD;
          6. History of allergic reactions, hypersensitivity or toxic reactions to aminoglycosides.&#xD;
&#xD;
          7. History of anaphylaxis.&#xD;
&#xD;
          8. Supine 12-lead ECG abnormalities at screening considered clinically significant.&#xD;
&#xD;
          9. Clinically significant vital sign abnormalities at screening.&#xD;
&#xD;
         10. History of significant drug or alcohol abuse within six months prior to screening.&#xD;
&#xD;
         11. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days (or 5 half-lives, whichever&#xD;
             is longer) prior to dosing, administration of a biological product in the context of a&#xD;
             clinical research study within 90 days prior to dosing, or concomitant participation&#xD;
             in an investigational study involving no drug or device administration.&#xD;
&#xD;
         12. Positive urine drug screen or alcohol test at screening.&#xD;
&#xD;
         13. Female subject with positive pregnancy test at screening.&#xD;
&#xD;
         14. Breast-feeding or pregnant subject within 6 months prior to study drug administration.&#xD;
&#xD;
         15. Use of any drugs known as strong inducer or inhibitor of hepatic drug metabolism&#xD;
             within 30 days prior to study drug administration.&#xD;
&#xD;
         16. Use of medication other than stable medications approved by the PI and topical&#xD;
             products without significant systemic absorption.&#xD;
&#xD;
         17. Use of prohibited medications as directed in the protocol.&#xD;
&#xD;
         18. Donation of plasma within 7 days prior to dosing. Donation or loss of blood within 30&#xD;
             days prior to the first dosing.&#xD;
&#xD;
         19. Any reason which, in the opinion of the PI, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
         20. Inability to be venipunctured and/or tolerate catheter venous access.&#xD;
&#xD;
         21. Presence of mitochondrial mutation(s) making the subject susceptible to aminoglycoside&#xD;
             toxicity.&#xD;
&#xD;
         22. Presence of signs of dehydration, recent history of neuromuscular blockade or&#xD;
             clinically significant history of vestibular impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inventiv Health Clinical -Research Pharmacy Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.eloxxpharma.com</url>
    <description>Description Eloxx Pharmaceuticals Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <results_first_submitted>November 5, 2020</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired Renal Function</keyword>
  <keyword>PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03776539/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03776539/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were treated at medical clinics. Groups 1-2 Screening start: January 4, 2019 Screening end: 8 April 2019 Group 3 Screening start: 9 May 2019 Screening end: 17 June 2019 Group 4 Screening start: 26 June 2019 Screening end: 30 June 2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mild Renal Impairment</title>
          <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
        </group>
        <group group_id="P2">
          <title>Moderate Renal Impairment</title>
          <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
        </group>
        <group group_id="P3">
          <title>Severe Renal Impairment</title>
          <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
        </group>
        <group group_id="P4">
          <title>Healthy Volunteers</title>
          <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Mild Renal Impairment eGFR 60 to 89 mL/min/1.73 m^2</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Moderate Renal Impairment eGFR 30 to 59 mL/min/1.73 m^2</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Severe Renal Impairment eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Healthy Volunteers eGFR &gt;=90 mL/min/1.73 m^2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="5.9"/>
                    <measurement group_id="B2" value="65.0" spread="10.4"/>
                    <measurement group_id="B3" value="61.8" spread="8.2"/>
                    <measurement group_id="B4" value="57.7" spread="2.1"/>
                    <measurement group_id="B5" value="62.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>mL/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.72" spread="9.25"/>
                    <measurement group_id="B2" value="40.07" spread="4.54"/>
                    <measurement group_id="B3" value="16.92" spread="9.77"/>
                    <measurement group_id="B4" value="100.25" spread="15.65"/>
                    <measurement group_id="B5" value="57.99" spread="34.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters- Plasma AUC0-24</title>
        <description>Area under the curve (AUC0-24) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
        <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, and 24 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters- Plasma AUC0-24</title>
          <description>Area under the curve (AUC0-24) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16877.94" spread="1714.57"/>
                    <measurement group_id="O2" value="32787.41" spread="7410.46"/>
                    <measurement group_id="O3" value="64895.29" spread="16967.68"/>
                    <measurement group_id="O4" value="15506.68" spread="3444.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters- Plasma Cmax</title>
        <description>Peak Plasma Concentration (Cmax) of ELX-02 following a single subcutaneous (SC) dose in subjects with normal renal function, mild, moderate, or severe renal impairment</description>
        <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 36, 48, 72, and 168 (Day 8) hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters- Plasma Cmax</title>
          <description>Peak Plasma Concentration (Cmax) of ELX-02 following a single subcutaneous (SC) dose in subjects with normal renal function, mild, moderate, or severe renal impairment</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2993.33" spread="280.33"/>
                    <measurement group_id="O2" value="3688.33" spread="525.56"/>
                    <measurement group_id="O3" value="4273.33" spread="947.49"/>
                    <measurement group_id="O4" value="2995.00" spread="568.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf</title>
        <description>Area under the curve (AUC0-inf) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
        <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 36, 48, 72, and 168 (Day 8) hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf</title>
          <description>Area under the curve (AUC0-inf) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16997.41" spread="1776.84"/>
                    <measurement group_id="O2" value="35179.57" spread="9198.37"/>
                    <measurement group_id="O3" value="110925.53" spread="49098.37"/>
                    <measurement group_id="O4" value="15214.30" spread="2913.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters - Plasma Tmax</title>
        <description>Time to maximum concentration (Tmax) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
        <time_frame>0.25, 0.5, 0.75, 1, 2, 4, 6, 12, and 24 hours after dosing.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters - Plasma Tmax</title>
          <description>Time to maximum concentration (Tmax) of ELX-02 plasma concentration following a single subcutaneous (SC) dose</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.75" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.75" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.73" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - Ae0-t</title>
        <description>Cumulative amount of unchanged drug excreted into urine (Ae0-t) of ELX-02 following a single subcutaneous (SC) dose</description>
        <time_frame>Pre-dose (first void in the morning of Day 1), 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36, 36-48, and 48-72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - Ae0-t</title>
          <description>Cumulative amount of unchanged drug excreted into urine (Ae0-t) of ELX-02 following a single subcutaneous (SC) dose</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.50" spread="19.37"/>
                    <measurement group_id="O2" value="72.10" spread="26.45"/>
                    <measurement group_id="O3" value="54.86" spread="8.74"/>
                    <measurement group_id="O4" value="69.22" spread="17.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetic Parameter - Rmax</title>
        <description>Maximum rate of urinary extraction (Rmax) of ELX-02 following a single subcutaneous (SC) dose</description>
        <time_frame>Pre-dose (first void in the morning of Day 1), 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36, 36-48, and 48-72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetic Parameter - Rmax</title>
          <description>Maximum rate of urinary extraction (Rmax) of ELX-02 following a single subcutaneous (SC) dose</description>
          <units>mg/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.18" spread="2.91"/>
                    <measurement group_id="O2" value="8.06" spread="5.91"/>
                    <measurement group_id="O3" value="3.11" spread="1.81"/>
                    <measurement group_id="O4" value="12.09" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Treatment-Emergent Adverse Events (TEAEs) [Safety]</title>
        <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
        <time_frame>1-8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impairment</title>
            <description>eGFR 60 to 89 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O2">
            <title>Moderate Renal Impairment</title>
            <description>eGFR 30 to 59 mL/min/1.73 m^2</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment</title>
            <description>eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers</title>
            <description>eGFR &gt;=90 mL/min/1.73 m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Treatment-Emergent Adverse Events (TEAEs) [Safety]</title>
          <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the signing of the consent form until follow-up visit on Day 8.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Mild Renal Impairment eGFR 60 to 89 mL/min/1.73 m^2</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Moderate Renal Impairment eGFR 30 to 59 mL/min/1.73 m^2</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Severe Renal Impairment eGFR &lt;30 mL/min/1.73 m^2, Not Requiring Dialysis</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Healthy Volunteers eGFR &gt;=90 mL/min/1.73 m^2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.1">Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decrease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director Clinical Trials</name_or_title>
      <organization>Eloxx Pharmaceuticals</organization>
      <phone>1-781-577-5300</phone>
      <email>CTI@eloxxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

